Abstracts tagged "SLE"

Abstract Number: 1811 • 2015 ACR/ARHP Annual Meeting
Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
April Jorge¹, Apinya Lertratanakul², Julia (Jungwha) Lee³, William Pearce¹, David McPherson⁴, Trina Thompson⁵, Emma Barinas-Mitchell⁶ and Rosalind Ramsey-Goldman¹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, IL, ³Department of Preventive Medicine, Biostatistics Collaboration Center, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴University of Texas Health Science Center, Houston, TX, ⁵Saint Francis University, Ebensburg, PA, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Women with SLE have an increased incidence of premature cardiovascular disease (CVD). Depression is also common among SLE patients. A relationship between depression and…
Abstract Number: 2081 • 2015 ACR/ARHP Annual Meeting
The SLE Workshop: An Evaluation of a Long-Standing Hospital-Based Psychoeducational Program
Melissa T. Flores¹, Roberta Horton¹, Jillian A. Rose¹, Stephen A. Paget² and Michael Lockshin³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York, NY, ³Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY
Background/Purpose: An evaluation was conducted of a monthly hospital-based psychoeducational support group, ongoing since 1985, for people with lupus. Each 2-hour session begins with a…
Abstract Number: 3085 • 2015 ACR/ARHP Annual Meeting
Platelet Activation and Endothelial Reactivity in the Pathogenesis of Tissue Inflammation/Injury in Systemic Lupus Erythematosus
Robert Clancy¹, Sokha Nhek², Jonathan Newman³, Janet Nwaukoni¹, Sara Rasmussen⁴, Jill P. Buyon¹, Maya Rubin⁵, Kristen Lee¹ and Jeffrey Berger⁵, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Medicine, Division of Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for widespread endothelial dysfunction, vascular thromboses, and premature cardiovascular disease. Enhanced platelet activation and…
Abstract Number: 94 • 2015 ACR/ARHP Annual Meeting
NGS Panel for the Detection of Monogenic SLE in Children: Initial Results
Alexandre Belot¹, Gillian Rice², Anne-Laure Mathieu¹, Brigitte Bader-Meunier³, Thierry Walzer¹, Tracy A. Briggs², James O'Sullivan⁴, Simon Wiliams⁵, Michael W. Beresford⁶, Yanick Crow^2,7 and GENIAL Investigators, UK JSLE Study Group, ¹INSERM U1111, Lyon, France, ²Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ³Pediatric Rheumatology & Immunology, Necker hospital, Imagine Institution, Paris, France, ⁴University of Manchester, Manchester, United Kingdom, ⁵University of Manchester, Manchester, France, ⁶Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁷Neuroinflammation, Institut Imagine, Paris, France
Background/Purpose: Next generation sequencing (NGS) represents a revolution in the field of molecular medicine, and offers a new approach to deciphering the pathogenesis of complex…
Abstract Number: 772 • 2015 ACR/ARHP Annual Meeting
Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays
John Conklin¹, Basil Jones², Tyler O'Malley³, Duncan Poling⁴, JoAnne Ligayon⁵, Leilani Wolover⁶, Ying Qu⁷, Claudia Ibarra⁸, Puja Chitkara⁹ and Thierry Dervieux³, ¹1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ²Exagen Diagnostics, Vista, CA, ³Research and Development, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics Inc., Vista, CA, ⁵Flow Cytometry, Exagen Diagnostics Inc., Vista, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷Exagen Diagnostic Inc, Vista, CA, ⁸Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁹Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA
Background/Purpose: Deregulation and activation of the classical complement system is known to be associated with systemic lupus erythematosus (SLE). As such, several investigators have proposed…
Abstract Number: 1074 • 2015 ACR/ARHP Annual Meeting
DNA Methylation Patterns in Naïve CD4+ T Cells Identify Epigenetic Susceptibility Loci for Malar Rash and Discoid Rash in Systemic Lupus Erythematosus
Paul Renauer¹, Patrick Coit¹, Matlock A. Jeffries², Joan T. Merrill³, W Joseph McCune⁴, Kathleen Maksimowicz-McKinnon⁵ and Amr H. Sawalha⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁵Rheumatology, Henry Ford Hospital, Detroit, MI, ⁶Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneous clinical manifestations, autoantibody production, and epigenetic dysregulation in T cells. We sought…
Abstract Number: 1813 • 2015 ACR/ARHP Annual Meeting
Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production
Jie An¹, Joshua Woodward², Mark Minie³, YuFeng Peng⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, Department of Medicine & Immunology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Bioengineering, University of Washington, Seattle, WA, ⁴Rheumatology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Department of Medicine & Immunology, University of Washington, Seattle, WA
Background/Purpose: Anti-malarial drugs (AMD) such as Hydroxychloroquine (HCQ) and Quinacrine (QC) are effective in the treatment of skin rash and arthritis in systemic lupus erythematosus…
Abstract Number: 2125 • 2015 ACR/ARHP Annual Meeting
Rheumatic and Non-Rheumatic Autoimmune Diseases in SLE Offspring
Julie Couture¹, Sasha Bernatsky², Susan Scott³, Christian A. Pineau² and Evelyne Vinet², ¹McGill University Health Centre, Montreal, QC, Canada, ²Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Autoimmune diseases (AID) have familial aggregation and frequently share a common genetic predisposition. Only few small uncontrolled studies have evaluated the risk of AID…
Abstract Number: 3127 • 2015 ACR/ARHP Annual Meeting
Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®
Chaim Putterman¹, D. Scott Batty², I.R. Cohen³, Nicole Jordan⁴, Debbie Rybak¹, Tamar Rubinstein¹, Keren Jakobi⁵, Rachel Sorek⁵, Anat Reiner-Benaim⁵, Yakov Blumenstein⁵ and Pennina Safer⁵, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray Inc., Richmond, VA, ³Weizmann Institute of Science, Rehovot, Israel, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel
Background/Purpose: Peripheral neurologic syndromes and central nervous system (CNS) manifestations are recognized as primary disease manifestations in systemic lupus erythematosus (SLE). Neuropsychiatric SLE (NPSLE) involves…
Abstract Number: 146 • 2015 ACR/ARHP Annual Meeting
Rates of Lipid Testing and Statin Prescription Filling Among U.S. Medicaid Recipients with SLE, 2007-2010
Sarah Chen¹, Michael A. Fischer², Hongshu Guan³, Medha Barbhaiya⁴ and Karen H. Costenbader⁵, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Internal Medicine, Weill Cornell Medical College, New York, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Given high cardiovascular disease (CVD) risks in SLE patients, lipid testing and statin prescription are widely advocated for those with elevated risks. We examined…
Abstract Number: 788 • 2015 ACR/ARHP Annual Meeting
Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies
Matteo Cesaroni¹, Jarrat Jordan¹, Jessica Schreiter¹, Marc Chevrier¹, Grace Wang², Cesar Calderon³, Alexa Piantone², Ian Gourley⁴, Stanley Cohen⁵, Scott Fretzin⁶, Anna Wozniacka⁷, Victoria P. Werth⁸ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, Spring House, PA, ³37 Derwen Dr., Janssen Research and Development, Havertown, PA, ⁴1329 Anthony Wayne drive, Janssen Research and Development, Wayne, PA, ⁵Metroplex Clinical Research Center, LLC, Dallas, TX, ⁶Dawes Fretzin Clinical Research Group, LLCC, Indianapolis, IN, ⁷Medical University of Lodz, Lodz, Poland, ⁸Philadelphia VA Medical Center, Philadelphia, PA
Background/Purpose: Sub-classification of Lupus Erythematosus (LE) patients is largely based on defined clinical criteria while biological factors associating with or contributing to these clinical features…
Abstract Number: 1116 • 2015 ACR/ARHP Annual Meeting
Decreased Expression of Negative Regulators of Toll-like Receptor Signaling and Increased TLR7 Responsiveness in Expanded IgD- CD27- B Cells from Systemic Lupus Erythematosus Patients
Scott Jenks¹, Benjamin Barwick² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Emory University, Altanta, GA, ³Medicine, Emory University, Atlanta, GA
Background/Purpose: B cell homeostasis is perturbed in SLE patients; in particular many patients with active disease have a large expansion of IgD- CD27- B cells…
Abstract Number: 1835 • 2015 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement
Arielle Fein¹, Caroline Figgie¹, Taylor Dodds², Joshua Wright-Chisem³, Michael Parks⁴, Lisa Mandl⁵, Edwin Su⁶, Jane E. Salmon^5,7, David J. Mayman⁴, Yuo-Yu Lee⁸, Mark P. Figgie² and Susan M. Goodman⁷, ¹Research, Hospital for Special Surgery, New York, NY, ²Orthopaedics, Hospital for Special Surgery, New York, NY, ³University of Illinois at Chicago College of Medicine, Chicago, IL, ⁴Orthopedics, Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶Orthopedic Surgery, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY
Background/Purpose: More Systemic Lupus Erythematosus (SLE) patients are undergoing total knee arthroplasty (TKA) with equivalent benefits to osteoarthritis (OA) patients. While post-surgical adverse events (AEs)…
Abstract Number: 2536 • 2015 ACR/ARHP Annual Meeting
The Role of Race/Ethnicity and SES in Adverse Pregnancy Outcome in SLE and Apl
Sancia Ferguson¹, Elianna Kaplowitz², Laura Trupin³, Edward H. Yelin⁴, Patricia P. Katz^3,5 and Jane E. Salmon⁶, ¹Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ²Hospital for Special Surgery, New York, NY, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, UC San Francisco, San Francisco, CA, ⁵Arthritis Research Group, University of California San Francisco, San Francisco, CA, ⁶Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) and Anti-Phospholipid Antibodies (aPL) have pregnancies with higher rates of preterm labor, preeclampsia, and fetal loss than healthy…
Abstract Number: 3157 • 2015 ACR/ARHP Annual Meeting
B Cell Profile As a Biomarker of Disease Segmentation and Flare Prognosis in SLE
Chungwen Wei¹, Bridget Neary², Jamie Biear³, Jennifer Barnard^3,4, Michelle Petri⁵, Alex Rosenberg⁶, Jennifer H. Anolik⁷ and Ignacio Sanz¹, ¹Rheumatology, Emory University, Atlanta, GA, ²Emory University, Atlanta, GA, ³Rheumatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ⁶University of Rochester, Rochester, NY, ⁷University of Rochester Medical Center, Rochester, NY
Background/Purpose: B cell abnormalities in SLE are well-established contributors to disease pathogenesis. Perturbation of B cell homeostasis in SLE is often described separately for each…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].